Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.

Patients with unfavorable intermediate-risk prostate cancer will be randomized between 6 versus 12 months of hormone therapy with radiation therapy. Patients may choose to receive hypofractionated radiation therapy or hypofractionated radiation therapy with high-dose rate brachytherapy. Hypofractionated radiation therapy refers to radiation therapy given fewer treatments, however higher doses per treatment.

NCT Number	NCT06855589
Lead Sponsor	Charles LeMoyne Hospital
Conditions	Prostate Cancer (Adenocarcinoma)
Enrollment	400 participants
Start Date	2025-03
Primary Completion	2033-03 (estimated)
Study Completion	2034-03 (estimated)
Updated on ClinicalTrials.gov	2025-03-04